Anti-BCMA Antibodies for Selective B-Cell Subset Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for agents that specifically target and manipulate various B cell subsets, particularly plasma cells, memory B cells, and naïve B cells, as these cells are implicated in diseases such as multiple myeloma and autoimmune disorders like systemic lupus erythematosus, and BCMA provides a marker for targeting these cells.
Innovation Solution
Development of antibodies that specifically bind to the B cell surface antigen BCMA, including monoclonal, chimeric, and humanized forms, which can deplete or manipulate B cell subsets by binding to specific epitopes on plasma cells, memory B cells, and naïve B cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are designed to specifically target BCMA on plasma cells and memory B cells, then therapeutic effectiveness against B-cell mediated diseases is improved, but the risk of affecting normal B cell function and causing immunosuppression increases
Solution Approach 1:
The antibody is designed to recognize and bind specifically to BCMA expressed on plasma cells and memory B cells, while deliberately avoiding binding to BCMA on naïve B cells. This localized targeting approach ensures therapeutic effectiveness against pathological B cell subsets without causing broad immunosuppression of the entire B cell population.
Solution Approach 2:
The B cell population is segmented into different subsets (plasma cells, memory B cells, naïve B cells) with distinct BCMA expression patterns. The antibody selectively targets specific segments (plasma cells and memory B cells) that are implicated in disease pathogenesis, while leaving other segments (naïve B cells) intact to maintain normal immune function.
2Reliability
If antibodies deplete plasma cells and memory B cells to reduce serum immunoglobulin levels, then treatment of autoimmune diseases and multiple myeloma is improved, but the ability to mount new immune responses is reduced
Solution Approach 1:
The antibody exerts its therapeutic effect locally on specific B cell subsets (plasma cells and memory B cells) that are responsible for producing pathogenic antibodies in autoimmune diseases and multiple myeloma. By targeting only these specific cell types rather than all B cells, the treatment reduces harmful immunoglobulin levels while preserving the adaptive immune system's ability to respond to new antigens through naïve B cells.
Solution Approach 2:
The antibody exploits the overexpression of BCMA on pathological plasma cells and memory B cells as a vulnerability, converting this characteristic into a therapeutic target. The high BCMA expression that normally supports survival and function of these cells becomes the basis for selective depletion, turning a protective mechanism into a therapeutic weakness.
3Measurement precision
If BCMA is used as a target marker for antibody therapy, then specificity for plasma cells and memory B cells is improved, but the complexity of identifying and characterizing BCMA expression patterns across B cell subsets increases
Solution Approach 1:
BCMA serves as a universal marker that performs multiple functions: it is used for characterizing B cell subsets, determining their differentiation status, and serving as a therapeutic target for antibody binding. This multi-functionality simplifies the overall approach by using a single marker for multiple purposes rather than requiring separate markers for each function.
Solution Approach 2:
The natural expression pattern of BCMA on different B cell subsets provides self-organizing information that facilitates identification and characterization. The differential expression levels of BCMA automatically serve as a built-in classification system, eliminating the need for complex external characterization methods and allowing researchers to identify B cell subsets based on their inherent BCMA expression profiles.
Data Source
AI summary
This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.